4 August 2023 in Science Advances
For clear cell renal cell carcinoma (ccRCC), lipid deposition plays important roles in the development, metastasis, and drug resistance. However, the molecular mechanisms underlying lipid deposition in ccRCC remain largely unknown. By conducting an unbiased CRISPR-Cas9 screening, we identified the epigenetic regulator plant homeodomain finger protein 8 (PHF8) as an important regulator in ccRCC lipid deposition. Moreover, PHF8 is regulated by von Hippel–Lindau (VHL)/hypoxia-inducible factor (HIF) axis and essential for VHL deficiency–induced lipid deposition. PHF8 transcriptionally up-regulates glutamate-ammonia ligase (GLUL), which promotes the lipid deposition and ccRCC progression. Mechanistically, by forming a complex with c-MYC, PHF8 up-regulates TEA domain transcription factor 1 (TEAD1) in a histone demethylation–dependent manner. Subsequently, TEAD1 up-regulates GLUL transcriptionally. Pharmacological inhibition of GLUL by l -methionine sulfoximine not only repressed ccRCC lipid deposition and tumor growth but also enhanced the anticancer effects of everolimus. Thus, the PHF8-GLUL axis represents a potential therapeutic target for ccRCC treatment.
1 May 2023 in International Journal of Nanomedicine
Background and Purpose: The early diagnosis and differential diagnosis of renal cell carcinoma (RCC) has always been a clinical difficulty and a research focus. Carbonic anhydrase IX (CA IX) is highly expressed on the cell membrane of RCC but is not expressed in normal renal tissues. In this study, nanobubbles (NBs) targeting CA IX with ultrasound and photoacoustic multimodal imaging capabilities were prepared to explore a new method for the diagnosis and differential diagnosis of RCC. Methods: Indocyanine green (ICG)-loaded lipid NBs (ICG-NBs) were prepared by using the filming rehydration method, and anti-CA IX polypeptides (ACPs) were attached to their surfaces to prepare CA IX-targeted NBs (ACP/ICG-NBs). The particle size, zeta potential and ICG encapsulation efficiency of these nanobubbles were measured, and their specific targeting and binding abilities to RCC cells were determined. The in vitro and in vivo ultrasound, photoacoustic and fluorescence imaging characteristics of these nanobubbles were also assessed. Results: The particle size of the ACP/ICG-NBs was 475.9 nm in diameter, and their zeta potential was − 2.65 mV. Laser confocal microscopy and flow cytometry both confirmed that ACP/ICG-NBs had specific binding activity and ideal affinity to CA IX-positive RCC cells (786-O) but not to CA IX-negative RCC cells (ACHN). The intensities of the in vitro ultrasound, photoacoustic and fluorescence imaging were positively correlated with the concentrations of ACP/ICG-NBs. In in vivo ultrasound and photoacoustic imaging experiments, ACP/ICG-NBs exhibited specific enhanced ultrasound and photoacoustic imaging effects in 786-O xenograft tumors. Conclusion: The ICG- and ACP-loaded targeted nanobubbles that we prepared had the capability of ultrasound, photoacoustic and fluorescence multimodal imaging and could specifically enhance the ultrasound and photoacoustic imaging of RCC xenograft tumors. This outcome has potential clinical application value for the diagnosis of RCC at the early stage and the differential diagnosis of benign and malignant kidney tumors.
18 February 2026 in Cancer Research
Immune checkpoint inhibitors (ICI) have transformed cancer therapy, yet their efficacy remains limited to a subset of patients, underscoring the need for robust predictive biomarkers and deeper mechanistic insights into treatment resistance. In this study, we identified a population of CCL5hiCD4+ T cells that were characterized by memory-like activation markers and strongly correlated with ICI therapeutic responses in bladder cancer. Functionally, these T cells enhanced antitumor immunity by promoting M1-like macrophage polarization through CCL5/CCR1 signaling. Importantly, tumor-derived prostaglandin E2 (PGE2) acted as a critical microenvironmental factor that suppressed the differentiation of CCR6hiCD4+ T cells into immunostimulatory CCL5hiCD4+ T cells, thereby driving resistance to ICI therapy. These findings extend the understanding of CD4+ T-cell heterogeneity and its role in shaping immune responses to ICI. By elucidating that CCL5hiCD4+ T cells enhance myeloid-mediated tumor control and that tumor-derived PGE2 disrupts CCL5hiCD4+ T-cell differentiation to promote immune evasion, this work highlights potential therapeutic strategies to improve ICI efficacy in bladder cancer. Significance: CCL5 hiCD4+ T cells with memory-like activated characteristics enhance antitumor immunity in bladder cancer by reprogramming macrophages, supporting the potential of these cells as biomarkers and targets to enhance immunotherapy efficacy.